TY - JOUR
T1 - Adverse Reactions With Oral and Parenteral Gold Preparations
AU - Tozman, Elaine C.S.
AU - Gottlieb, Norman L.
PY - 1987/6
Y1 - 1987/6
N2 - Auranofin (triethylphosphine gold), an oral gold preparation, has recently been made available, and along with injectable gold preparations, is of therapeutic value for rheumatoid arthritis. Serious gold toxicity is uncommon, and drug-related deaths rare. Many potential adverse reactions are similar, including dermatitis, stomatitis, thrombocytopenia, leucopenia, and proteinuria, generally with increased incidence in the injectable gold-treated patients. Oral gold is associated with benign lower gastrointestinal side effects, including diarrhoea, loose stools and abdominal cramps that are often dose-related and resolve spontaneously. The incidence of severe reactions such as thrombocytopenia, aplastic anaemia and exfoliative dermatitis is lower with oral gold than injectable preparations, and contributes to a superior risk-benefit ratio. The treatment of gold toxicity depends on the type and extent of organ involvement.
AB - Auranofin (triethylphosphine gold), an oral gold preparation, has recently been made available, and along with injectable gold preparations, is of therapeutic value for rheumatoid arthritis. Serious gold toxicity is uncommon, and drug-related deaths rare. Many potential adverse reactions are similar, including dermatitis, stomatitis, thrombocytopenia, leucopenia, and proteinuria, generally with increased incidence in the injectable gold-treated patients. Oral gold is associated with benign lower gastrointestinal side effects, including diarrhoea, loose stools and abdominal cramps that are often dose-related and resolve spontaneously. The incidence of severe reactions such as thrombocytopenia, aplastic anaemia and exfoliative dermatitis is lower with oral gold than injectable preparations, and contributes to a superior risk-benefit ratio. The treatment of gold toxicity depends on the type and extent of organ involvement.
UR - http://www.scopus.com/inward/record.url?scp=0023266022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023266022&partnerID=8YFLogxK
U2 - 10.1007/BF03259863
DO - 10.1007/BF03259863
M3 - Article
C2 - 3298922
AN - SCOPUS:0023266022
VL - 2
SP - 177
EP - 189
JO - Drug Safety
JF - Drug Safety
SN - 0114-5916
IS - 3
ER -